The role of B7-1 in minimal change nephropathy and FSGS has been controversial [87]; nonetheless, Ha and others have demonstrated the amelioration of podocyte injury and proteinuria with therapies that reduce B7-1 expression [82,84,88]. Here, CD80 is linked to focal segmental glomerulosclerosis.